IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 2025...

Related Keywords

Sydney ,New South Wales ,Australia ,Russia ,Ukraine ,Yujiros Hata ,Werner Helicase ,Darovasertib Monotherapy ,Michael White ,Exchange Commission ,Pfizer ,Glaxosmithkline ,Biosciences Inc ,Vincent Hospital Sydney ,Program Updates ,Nasdaq ,Pol Theta ,Chief Executive Officer ,Senior Vice President ,Chief Scientific Officer ,Pol Theta Helicase ,Crizotinib Combination ,Orphan Drug ,Investigator Sponsored Trial ,Hospital Sydney Limited ,Investor Relations ,Quarterly Report ,Vice President ,Chief Financial Officer ,Ideaya Biosciences ,Nc ,